Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Antineoplastic Agents
Antineoplastic Agents
Carcinoma, Squamous Cell
Carcinoma, Squamous Cell
Checkpoint Kinase 1
Checkpoint Kinase 1
Combined Modality Therapy
Combined Modality Therapy
Female
Female
Gene Expression Profiling
Gene Expression Profiling
Humans
Humans
Kaplan-Meier Estimate
Kaplan-Meier Estimate
Male
Male
Middle Aged
Middle Aged
Neoplasm Metastasis
Neoplasm Metastasis
Neoplasm Staging
Neoplasm Staging
Protein Kinase Inhibitors
Protein Kinase Inhibitors
Pyrazines
Pyrazines
Pyrazoles
Pyrazoles
Retreatment
Retreatment
Treatment Outcome
Treatment Outcome
authors with profiles
Kathleen Moore